EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Vision & Ocular Peptides
Vision peptides used in ophthalmology range from approved drugs that treat retinal disease and corneal damage to investigational compounds targeting neurotrophic keratitis and ocular inflammation.
The eye is uniquely suited to peptide therapy: its immune-privileged status, limited systemic exposure from topical or intravitreal delivery, and well-defined anatomy make it one of the most tractable organs for peptide drug development.
Cluster at a Glance
|
7 Compounds Covered |
2 Approved Drug |
1 Clinical Trials |
3 Pilot / Limited Human Data |
1 Preclinical Only |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
Two FDA-approved drugs anchor this cluster. Anti-VEGF peptides (ranibizumab/Lucentis, brolucizumab/Beovu) revolutionized the treatment of wet age-related macular degeneration and diabetic retinopathy. Cenegermin (Oxervate) is the first topical nerve growth factor approved for neurotrophic keratitis. RGN-259 (thymosin beta-4 eyedrop) is the most advanced pipeline compound, with Phase III data. The remaining compounds repurpose systemically studied peptides for ocular-specific applications—NGF eyedrops, intravitreal Octreotide for diabetic retinopathy, and the SP/IGF-1 combination for corneal nerve regeneration.
In This Article
Compounds in This Cluster
All 7 compounds in the Vision & Ocular Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 3
The Approved Ocular Drugs
FDA-approved peptide therapies that have transformed ophthalmology.
Group 2 of 3
The Ocular Pipeline
Investigational peptide therapies at various stages of clinical development for eye diseases.
|
|
|
||||||||||||
|
Group 3 of 3
The Early-Stage Repurpose
A systemically studied peptide being investigated for an ocular-specific application.
|
How These Compounds Relate
The seven compounds in this cluster target three distinct pathological processes in the eye: abnormal blood vessel growth (anti-VEGF), nerve damage and loss of corneal sensation (Cenegermin, RGN-259, NGF, SP/IGF-1), and inflammation-driven tissue damage (Octreotide, PL-8177). Anti-VEGF therapy is the established standard: intravitreal injections of ranibizumab or brolucizumab block the vascular endothelial growth factor that drives neovascularization in wet AMD and diabetic retinopathy.
The neurotrophic compounds represent the emerging frontier. Cenegermin proved that topical nerve growth factor can regenerate corneal nerves—a first in ophthalmology. RGN-259 (thymosin beta-4) approaches corneal healing from a different angle: anti-inflammatory and pro-migratory effects that help epithelial cells close wounds. The SP/IGF-1 combination mimics the natural neurotrophic signaling that maintains corneal innervation.
Intravitreal Octreotide is a creative repurposing—somatostatin receptors are expressed in the retina, and their activation reduces vascular permeability and neuroinflammation. PL-8177’s ocular investigation reflects the growing recognition that melanocortin anti-inflammatory signaling may be particularly suited to the immune-privileged eye. Both represent early-stage attempts to expand the peptide ophthalmology toolkit beyond the anti-VEGF and neurotrophic categories.
| Shared Mechanism | Compounds |
|
Anti-Angiogenesis Blocks VEGF-mediated abnormal blood vessel growth and vascular leakage in the retina. |
Anti-VEGF Peptides |
|
Neurotrophic Regeneration Promotes corneal nerve regrowth and epithelial healing through growth factor and neuropeptide signaling. |
Cenegermin, NGF (Ocular), SP/IGF-1 Ocular |
|
Anti-Inflammatory / Pro-Healing Reduces ocular inflammation and promotes wound closure through anti-inflammatory and pro-migratory mechanisms. |
RGN-259, PL-8177 (Ocular) |
|
Somatostatin Receptor Modulation Activates retinal somatostatin receptors to reduce vascular permeability and neuroprotective inflammation. |
Octreotide (Intravitreal) |
Plain English
Your eye is one of the best organs for peptide drugs because it is small, contained, and you can deliver drugs directly to it. Two approved drugs here have already changed ophthalmology: anti-VEGF injections stop abnormal blood vessels from destroying the retina, and Cenegermin (nerve growth factor eyedrops) regenerates damaged corneal nerves. The pipeline builds on these successes—RGN-259 uses a different peptide for corneal healing, the SP/IGF-1 combo tries to restore corneal sensation, and two repurposed peptides (Octreotide, PL-8177) explore whether their systemic effects can be harnessed specifically in the eye.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.